Sea King Bio announced that a new type of tumor vascular blocker has been approved for clinical use in China.

Screenshot Source: CDE Official Website According to the announcement, HW130 injection is a new type of tumor vascular blocker independently developed by Hai wang pharmaceutical with independent intellectual property rights.
preclinical studies have shown that HW130 injections have significant effects of tumor vascular damage and significantly reduced tumor mortality, significantly improving the clinical benefits of comprehensive tumor therapy.
addition, the HW130 has minor damage to normal organ tissue and is highly targeted and safe.
public information shows that, as a class of optimized new compounds, HW130 is very special in nature, researchers use nano-insoluble and other cutting-edge innovative technologies to overcome the problem of pharmaceutical.
, they establish and validate quality control methods in a number of key links, from raw materials to preparations, to ensure that products are safe, effective and controlled in quality.
the United States, the HW130 injection was approved in January 2020 for Phase 1 human clinical trials.
an earlier press release from Sea King Bio, this is the company's third independent drug to complete its declaration at the FDA and will conduct international multi-center clinical studies.
another innovative product in the company's new drug development is napthals.
This is a new drug targeted at anti-tumor by Sea King Biogenic Small Molecules, a new powerful and highly selective EGFR/HER2 inhibitor that irreversibly inhibits the function of EGFR and related family proteins such as HER2, inhibits the conduction of tumor cell proliferation signals, and fights non-small cell lung cancer or related tumors such as stomach cancer.
, the product is currently conducting clinical trials in China and the United States.
: (1) Announcement of approval for drug clinical trials for HW130 injections. Retrieved Oct 22, 2020, from the Sea King Research Institute, another innovative drug, HW130 injections, was approved by the FDA to enter human clinical trials.